Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune diseases. Its mission is to create safe and effective oral treatments that address the therapeutic gap in the current treatment paradigm. Landos has a portfolio of novel targets anchoring two libraries of immunometabolic modulation pathways, including four potentially first-in-class, once-daily, oral therapies targeting multiple indications in the immunology space. Landos is currently focused on advancing the clinical development of NX-13 in UC. Landos initiated the NEXUS Phase 2 proof-of-concept trial (NCT05785715) in the second quarter of 2023 and plans to report topline results in the fourth quarter of 2024. For more information, please visit www.landosbiopharma.com.